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Abstract
 
Syncytia arising from the fusion of cells expressing a lymphotropic human immunodeficiency
virus (HIV)-1–encoded envelope glycoprotein complex (Env) gene with cells expressing the
CD4/CXCR4 complex undergo apoptosis through a mitochondrion-controlled pathway ini-
tiated by the upregulation of Bax. In syncytial apoptosis, phosphorylation of p53 on serine 15
(p53S15) precedes Bax upregulation, the apoptosis-linked conformational change of Bax, the
insertion of Bax in mitochondrial membranes, subsequent release of cytochrome 
 
c
 
, caspase acti-
vation, and apoptosis. p53S15 phosphorylation also occurs in vivo, in HIV-1
 
 
 
 donors, where it
can be detected in preapoptotic and apoptotic syncytia in lymph nodes, as well as in peripheral
blood mononuclear cells, correlating with viral load. Syncytium-induced p53S15 phosphoryla-
tion is mediated by the upregulation/activation of mammalian target of rapamycin (mTOR),
also called FKBP12-rapamycin-associated protein (FRAP), which coimmunoprecipitates with
p53. Inhibition of mTOR/FRAP by rapamycin reduces apoptosis in several paradigms of syn-
cytium-dependent death, including in primary CD4
 
 
 
 
 
lymphoblasts infected by HIV-1. Con-
comitantly, rapamycin inhibits p53S15 phosphorylation, mitochondrial translocation of Bax,
loss of the mitochondrial transmembrane potential, mitochondrial release of cytochrome 
 
c
 
, and
nuclear chromatin condensation. Transfection with dominant negative p53 has a similar antiap-
optotic action as rapamycin, upstream of the Bax upregulation/translocation. In summary, we
demonstrate that phosphorylation of p53S15 by mTOR/FRAP plays a critical role in syncytial
apoptosis driven by HIV-1 Env.
Key words: cell death • envelope glycoprotein complex • human immunodeﬁciency virus • 
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Introduction
 
HIV-1 infection can cause apoptosis via a variety of mecha-
nisms, some of which rely on the intricate virus host cell in-
teraction (in vitro) and some of which involve activation of
the host’s inflammatory and immune systems (in vivo; refer-
ences 1 and 2). The envelope glycoprotein complex (Env)
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(gp120/gp41) appears to be one of the dominant apoptosis-
inducing molecules encoded by the HIV-1 genome. Env
expressed on the plasma membrane of infected cells can in-
teract with CD4 and a suitable coreceptor (e.g., CXCR4)
to trigger cell-to-cell fusion; the resulting syncytia subse-
quently undergo apoptosis. This applies to primary CD4
 
 
 
 T
lymphocytes inoculated by HIV-1 (references 3 and 4), as
well as to cell lines stably transfected with human 
 
CD4
 
 co-
cultured with cells expressing a lymphotropic HIV-1 
 
Env
 
gene (5–7). A positive correlation between CD4
 
 
 
 T cell de-
cline and infection by syncytium-inducing HIV-1 or SIV-1
variants has been established in vitro (3, 4, 8, 9) and, more
importantly, in vivo, in humans with AIDS (10, 11), hu-
manized severe combined immunodeficient mice (12), and
monkeys (13). This suggests that fusion-induced apoptosis is
relevant to AIDS pathogenesis, although syncytia are rela-
tively infrequent in lymphoid tissues of HIV-1
 
 
 
 donors
(14). In lymph nodes from HIV-1–infected individuals,
syncytia express markers of early apoptosis such as tissue
transglutaminase (tTGase; reference 15). The scarcity of
syncytia in vivo may thus be attributed to their rapid ap-
optotic degeneration and phagocytic removal, yet does not
argue against the pathophysiological importance of fusion-
induced apoptosis.
The apoptosis-associated activation of caspases can be
triggered by two pathways (16, 17). In the “extrinsic”
pathway, the ligation of plasma membrane death receptors
(e.g., CD95, TNF-R) leads to the recruitment of caspase-8
to the receptor complex, culminating in its proteolytic
autoactivation (16). In the “intrinsic” pathway, mitochon-
drial membrane permeabilization (MMP) results in the re-
lease of cytochrome 
 
c
 
 (Cyt. 
 
c
 
) from the mitochondrial in-
termembrane space. Once in the cytosol, Cyt. 
 
c 
 
triggers
the oligomerization of Apaf-1, which in turn recruits pro-
caspase-9 and procaspase-3 into the apoptosome, the cas-
pase activation multiprotein complex (18). MMP may be
elicited by a variety of different proapoptotic second mes-
sengers (e.g., Ca
 
2
 
 
 
, ganglioside GD3, reactive oxygen spe-
cies), as well as proapoptotic members of the Bcl-2 family
such as Bax, Bak, Bid, Bim, etc. (17). Nuclear DNA dam-
age is one of the best studied initiators of the intrinsic
pathway of apoptosis (19, 20). DNA double-strand breaks
are sensed by two enzymes from a protein family termed
the phosphatidylinositol kinase-related kinases (or PIKKs),
in particular ataxia teleangiectasia mutated (ATM) and
DNA-dependent protein kinase (DNA-PK). UV-induced
damage is mainly sensed by ataxia teleangiectasia Rad3 re-
lated (ATR), yet another member of the PIKK family.
DNA-PK, ATM, ATR, as well as the downstream DNA-
damage-induced kinases Chk1 (activated by UV) and
Chk2 (activated by ionizing radiation), phosphorylate
serine residues within the NH
 
2
 
 terminus of p53, a modifi-
cation that by itself may increase its transactivating func-
tion and/or inhibits the interaction of p53 with MDM2
and so prevents degradation of the p53 protein, which ac-
cumulates and can act as a transcription factor, stimulating
the expression of several MMP-inducing proteins includ-
ing Bax (21).
Syncytial apoptosis induced by the interaction between
Env and CD4/CXCR4, in the absence of viral infection,
involves a mitochondrial pathway characterized by the fol-
lowing sequence of events: (i) translocation of Bax from
the cytosol to mitochondria; (ii) Bax-mediated MMP with
loss of the mitochondrial transmembrane potential (
 
  
 
m
 
),
release of apoptogenic intermembrane proteins, in particu-
lar apoptosis-inducing factor and Cyt. 
 
c
 
, (iii) caspase activa-
tion, and (iv) nuclear chromatin condensation (6). This se-
quence of events has been confirmed, in principle, for
HIV-1–infected HeLa cells transfected with CD4, as well
as for primary CD4
 
 
 
 lymphoblasts infected with lympho-
tropic HIV-1 (6, 22). No information was available on the
premitochondrial proapoptotic signal transduction path-
ways involved in Env-induced syncytial apoptosis. There-
fore, we have employed a systematic approach, based on
proteomics and inhibitor screening assays, to define such
upstream signals accounting for the induction and mito-
chondrial translocation of Bax. Here we show that phos-
phorylation of p53, via a pathway not related to DNA
damage, is involved in Env-induced syncytial apoptosis. In-
deed, it appears that p53 is phosphorylated on serine 15 by
mammalian target of rapamycin (mTOR), also called
FKBP12-rapamycin-associated protein (FRAP), a protein
from the PIKK family that previously has been suggested to
serve as a master regulator of the balance between protein
synthesis and degradation (23), thereby participating in the
control of cell size (24, 25) and perhaps in oncogenic trans-
formation (26).
 
Materials and Methods
 
Cells Lines, Transfection, Microinjection, and Comet Assays.
 
HeLa cells transfected with the 
 
Env
 
 gene of HIV-1 LAI (HeLa
Env, reference 27) and HeLa cells transfected with CD4 (HeLa
CD4, reference 5) were cultured alone or together (1:1 ratio) in
medium supplemented with 10% FCS, as described previously (5,
6, 27). Mouse embryonic fibroblasts (MEFs) with different geno-
types (p53
 
 
 
/
 
 
 
, p53
 
 
 
/
 
 
 
, p53
 
 
 
/
 
 
 
) were a gift from T. Jacks, MIT,
Boston, MA. MEFs were cultured on coverslips and were fused
with polyethylene glycol (PEG) (45 s of incubation with pre-
warmed [37
 
 
 
C] 50% wt/vol PEG from Sigma-Aldrich, 1,450, in
Ca
 
2
 
 
 
-free PBS, pH 7.2; preceded by two washings with FCS-free
medium), followed by four washings with complete medium.
 
N
 
-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.
fmk, used at 100 
 
 
 
M) was added each 24 h, whereas other
inhibitors were added only once, from the beginning of the cul-
ture. Transfection with pcDNA3.1 vector only, pBR322 plasmid
constructs containing wild-type p53 or mutant (H175, H273)
p53 (28) (gift of T. Soussi, Institut Curie, Paris, France), ex-
pressed under the control of the cytomegalovirus promoter, lu-
ciferase, terminal oligopyrimidine (TOP)-luciferase constructs
(29) (gift of J. Chen, Illinois University, Urbana, IL), or a p53-respon-
sive enhanced green fluorescent protein (GFP) plasmid (gift
from K. Wiman, Karolinska Cancer Center, Stockholm, Sweden)
was performed by electroporation (30) 24 h before coculture of
HeLa CD4 and HeLa Env cells. The p53-responsive GFP plas-
mid was generated by replacing the luciferase gene in PG13PY
Luc (a luciferase construct containing 13 repeats of the p53-bind-
ing oligonucleotide 5
 
 
 
-CCTGCCCTGGGACTTGCCTGG-3
 
 
 
, 
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gift from Bert Vogelstein, Howard Hughes Medical Institute,
Baltimore, MD) with an EcoA7III-MluI fragment from pEGFP-
C1. In some experiments, all syncytia growing on a premarked
V-shaped area of a coverslip (
 
 
 
200 per experiment) were micro-
injected into the cytoplasm (31), with PBS only, pH 7.2, recom-
binant human Bcl-2 (amino acids 1–218; 500 ng/
 
 
 
l; reference
32), a mAb specific for mTOR/FRAP (BD Transduction Labo-
ratories) or an isotype-(IgG2a) matched LAMP-1 mAb (Onco-
gene Research Products) (both at 50 ng/
 
 
 
l). Comet assays were
performed using a kit from Trevigen, on HeLa Env cells (un-
treated or treated with 100 
 
 
 
M H
 
2
 
O
 
2
 
 for 30 min) or 24-h-old
HeLa Env/CD4 syncytia (nonapoptotic adherent or apoptotic
cells).
 
Patients’ Samples.
 
Peripheral blood samples were obtained
from 49 HIV-infected individuals from the National Institute for
Infectious Diseases (IRCCS Lazzaro Spallanzani, Rome, Italy).
Patients (mean age 34 
 
 
 
 11 y, 
 
n 
 
 
 
 49) were included in this
study according to the following criteria: asymptomatic HIV-1
infection (A, CDC 1993), under at least 2 mo of antiretroviral
therapy interruption, CD4
 
 
 
 T lymphocytes in peripheral blood
in the range of 300–600/
 
 
 
l, plasma HIV-RNA levels 
 
 
 
80 copies
per milliliter, no treatment with IFNs or corticosteroids, absence
of infection with hepatitis C virus, hepatitis B virus, and autoim-
mune disease. All patients provided informed written consent ac-
cording to the Ethical Committee. PBMCs were isolated by Fi-
coll/Hypaque (Amersham Pharmacia Biotech) centrifugation of
heparinized blood from either healthy donors and HIV-seroposi-
tive individuals and fixed with 4% formaldehyde in PBS, pH 7.2.
Plasma HIV-1 RNA levels were determined by the Nucleic Acid
Sequence Based Amplification (NASBA) procedure (HIV-1
RNA QT assay; Organon Teknika). Plasma levels of HIV-1
RNA were expressed as HIV-RNA copies per milliliter with a
threshold level of 80 copies per milliliter. Biopsies of axillary
lymph nodes, obtained from healthy donors and HIV-1
 
 
 
 asymp-
tomatic patients, naive for antiretroviral therapy, were immedi-
ately fixed with 10% formalin neutral buffered, dehydrated, and
paraffin embedded.
 
HIV-1 Infection.
 
5 
 
 
 
 10
 
6
 
 HeLa CD4 cells were cultured in
the presence of 2.5 
 
 
 
 10
 
6
 
 chronically HIV-1–infected H9/IIIB
cells (obtained from R.C. Gallo, National Institutes of Health,
Bethesda, MD) in 5 ml of RPMI 1640 supplemented with 10%
heat inactivated FCS and 2 mM glutamine. Alternatively, CEM
cells containing a plasmid encoding GFP driven by the HIV-1
long terminal repeat (33); clone 8D6; obtained from J. Corbel,
University of California at San Diego, San Diego, CA) were
cocultured (1:1 ratio) with HIV-1–infected H9/IIIB cells.
Cell-to-cell fusion was assessed by determining the GFP-
dependent fluorescence (excitation 458 nm, emission 515 nm)
in a Fluoroscan plate fluorometer (Labsystems). Alternatively,
cells were resuspended in a solution containing 3.4 mM so-
dium citrate, 0.05 mg/ml propidium iodide, 0.1 mM EDTA, 1
mM Tris, pH 8, and 0.1% Triton X-100 (34), incubated for 60
min at reverse transcription, and analyzed for DNA content in
a FACScalibur™ (Becton Dickinson). This method allows for
the quantitation of all apoptotic nuclei, including those of syn-
cytia, which are disrupted by the hypotonic buffer. CD4
 
 
 
 T
cells were purified from freshly isolated PBMCs by immuno-
magnetic negative selection (Stem Cell Technologies). Cells
were cultured for 2 d in RPMI 1640 medium supplemented
with 10% FCS (GIBCO BRL) containing 3 
 
 
 
g/ml PHA
(Sigma-Aldrich) and 6 U/ml IL-2 (IL-2; Boehringer Mann-
heim). For HIV-1 infection, 10 
 
 
 
 10
 
6
 
 cells were incubated
with the T cell line–adapted HIV-1 strain IIIB (500 ng of p24)
for 4 h at 37
 
 
 
C. After washing out unabsorbed virus, cells were
cultured at a density of 10
 
6 
 
cells per milliliter in RPMI 1640
medium containing 20% FCS and 10 UI/ml IL-2 in 24-well
plates. 2 d after infection, when the first syncytia appeared in
the infected cultures, infected and uninfected cultures were
treated with 5 
 
 
 
g/ml AMD3100, 100 
 
 
 
M ZVAD.fmk, or the
indicated dose of rapamycin. Infection was allowed to proceed
for 2 more d. At this time mitochondrial function and nuclear
morphology were evaluated after JC1/Hoechst staining as de-
scribed below. Viral replication was evaluated by measuring the
level of HIV-1 core protein p24 in the supernatant (Innogenet-
ics ELISA kit). Promonocytic U937 cell line were infected at a
multiplicity of infection of 0.5 TCID
 
50
 
 per cell, for 2 h at 37
 
 
 
C
washed three times in PBS.
 
Quantitation of Protein Expression Levels.
 
Protein samples were
simultaneously prepared from HeLa Env and HeLa CD4 single
cells (SCs) mixed at a 1:1 ratio in lysis buffer (0 control) or
from HeLa Env/CD4 syncytia obtained after 18 or 36 h of co-
culture. These samples were then processed by the PowerBlot
facility (Becton Dickinson), which determined the expression
level of 
 
 
 
800 different signal-transducing proteins using a
combination of SDS-PAGE (5–15% gradient), immunoblotting
with specific monoclonal antibodies revealed by a secondary
goat anti–mouse horseradish peroxidase, capture of chemilu-
minesence data by a CDD camera, and computerized process-
ing of densitometric data (for details consult www.translab.
com/TOC.shtml). Data were normalized by dividing the signal
obtained for each protein by the sum of signals obtained for all
800 proteins for one given sample. For proteins revealing a
variation in the expression of at least 20%, determined in two
initial runs, expression levels were verified in a third indepen-
dent experiment.
 
Immunoblots and Coimmunoprecipitation.
 
Aliquots of total pro-
tein extracts (40 
 
 
 
g), were run on SDS-PAGE and electroblot-
ted overnight at 4
 
 
 
C onto nitrocellulose membrane. Immuno-
detection involved antibodies specific for p53, Bax, Bcl-2,
mTOR/FRAP (BD Transduction Laboratories), phosphoryla-
tion of p53 on serine 15 (p53S15P) (Cell Signaling Technology),
appropriate secondary antibodies (goat anti–rabbit or goat anti–
mouse; Bio-Rad Laboratories) conjugated to horseradish peroxi-
dase, and the enhanced ECL chemiluminescence detection sys-
tem (Amersham Pharmacia Biotech). Equal loading and transfer
was monitored by Ponceau red staining of nitrocellulose mem-
branes. For immunoprecipitation, lysates from sonicated, Triton
X-100-solublized cells (60 
 
 
 
g protein in 100 
 
 
 
l PBS with pro-
tease inhibitors) were incubated for 90 min at 37
 
 
 
C with 500 ng
affinity-purified rabbit polyclonal antibodies specific for p53,
p53S15P, or Bcl-2, followed by addition of 10 
 
 
 
l-packed pro-
tein A/G-agarose beads (30 min, 37
 
 
 
C; Santa Cruz Biotechnol-
ogy, Inc.), vigorous washing of the pellet (10 min at 10,000 
 
g
 
,
3 
 
 
 
) in PBS, 5% SDS PAGE, and immunodetection with an
mTOR/FRAP-specific mAb.
 
Fluorescence Staining of Live Cells, Immunofluorescence, and Immu-
nocytochemistry.
 
For the simultaneous assessment of mitochon-
drial and nuclear features of apoptosis, live cells were stained
with the potentiometric dye 5,5
 
 
 
,6,6
 
 
 
-tetrachloro-1,1
 
 
 
, 3,3
 
 
 
-tet-
raethylbenzimidazolylcarbocyanine iodide (2 
 
 
 
M JC-1; Molecu-
lar Probes), as well as Hoechst 33342 (2 
 
 
 
M; Sigma-Aldrich) for
30 min at 37
 
 
 
C in complete culture medium (6). A rabbit antise-
rum specific for p53S15P was used on paraformaldehyde (4% wt:
vol) and picric acid-fixed (0.19% vol:vol) cells and revealed with
a goat anti–rabbit IgG conjugated to PE (Southern Biotechnol-
ogy Associates, Inc.). Cells were also stained for the detection of 
1100
 
HIV–Env–induced Apoptosis
Cyt-c
 
 
 
(mAb 6H2.B4 from BD PharMingen), Hsp60 (mAb
H4149 from Sigma-Aldrich), Bax (mAb 6A7; BD PharMingen),
p21 (mAb EA10; Oncogene Research Products), MDM2 (mAb
IF2; Oncogene Research Products), mTOR/FRAP (mAb 3O;
BD Transduction Laboratories), all revealed by a goat anti–
mouse IgG ALEXA488 conjugate; Molecular Probes), and/or
chromatin (Hoechst 33342; reference 35). Immunocytochemical
staining was performed using polyclonal anti-p53S15P or mono-
clonal tTG (Neomarkers) antibodies. A biotinylated goat anti–
mouse or anti–rabbit IgG, as a secondary antibody, was used,
followed by a preformed horseradish peroxidase-conjugated
streptavidin (Biogenex). The reaction was developed using ami-
noethylcarbazole and 3-3
 
 
 
 diaminobenzidine (Biogenex) as
chromogenic substrates and 0.01% H
 
2
 
O
 
2
 
. Cells were counter-
stained in Mayer’s acid hemalum. Endogenous peroxidase activ-
ity was blocked by preincubation with 3% H
 
2
 
O
 
2
 
. Results were
quantified by two independent investigators on an average of
500 cells.
 
Results and Discussion
 
Early Phosphorylation of p53 on Serine 15 in HIV-1 Env-
induced Syncytial Apoptosis.
 
Syncytia formed by coculture
of two different HeLa cell lines expressing HIV-1 Env or
CD4/CXCR4 spontaneously undergo apoptosis (6, 7).
Among a panel of different apoptosis-regulatory proteins,
we found only one major alteration, namely an upregula-
tion of Bax that is well detectable 36 h after syncytium for-
mation (Fig. 1 A). Significant alterations were also found in
the expression level of the proapoptotic proteins Bid
(which is downregulated) and caspase-7 (which is upregu-
lated by 
 
 
 
50%). Whereas total p53 levels did not change
after formation of syncytia, an increased phosphorylation
of serine 15 (but not serines 6, 9, 20, 37, and 397) of p53
(p53S15) was detected, using a panel of phosphoserine
epitope-specific antibodies (Fig. 1 B). Phosphorylated
Figure 1. Expression levels of apoptosis-
regulatory proteins and p53S15 phosphory-
lation in syncytia. (A) Alteration in protein
expression levels determined by quantitative
immunoblot analysis. The percentage
changes of the expression levels in Bax, Bid,
and caspase-7 are shown after 18 and 36 h
of coculture of HeLa Env and HeLa CD4
cells. Results are means of three indepen-
dent determinations   SEM. *P    0.01.
The right panel lists apoptosis-regulatory
proteins which were detectable in HeLa
cells and whose expression level did not
change significantly (by  20%) within 36 h
after syncytium formation. (B) Immuno-
blots of p53, p53Ser15P, Bax, and Bcl-2 at
different intervals of syncytium formation.
(C) Immunofluorescence detection of
p53S15P (red fluorescence, left) in syncytia
counterstained with the nuclear dye
Hoechst 33342 (blue fluorescence, right).
(D) Frequency of p53S15P  and apoptotic
cells among syncytia (Syn) and SCs con-
tained in cocultures of HeLa Env and HeLa
CD4 cells. (E) Absence or presence of the
conformational change of Bax detectable
with a monoclonal antibody specific for the
NH2-terminal Bax domain (green fluores-
cence) among 24-h-old p53S15P  syncytia
(red nuclear fluorescence). Note that some
cells lack Bax immunoreactivity (left)
whereas others exhibit a cytoplasmic, in part
punctate staining pattern (right). (F) Subcel-
lular localization of Cyt. c (green) in 24-h-
old p53S15P  syncytia (red). Note the mi-
tochondrial (punctate) staining pattern (left)
or the diffuse pattern (right) indicative of
mitochondrial Cyt. c release. (G) Quantita-
tion of Bax and Cyt. c translocation among
p53S15P  and p53S15P  syncytia, 24 or 48 h
after initiation of coculture. (H) Effect of
the pancaspase inhibitor Z-VAD.fmk on
p53S15 phosphorylation. Hela Env and
HeLa CD4 cells were cocultured for 24 h in
the presence or absence of Z-VAD.fmk,
followed by determination of the frequency
of p53S15P  cells and of cells exhibiting chromatin condensation. (I) Effect of Bcl-2 on p53S15 phosphorylation. Syncytia (6 h) were microinjected with
recombinant Bcl-2 protein or sham injected, and the frequency of p53S15P  cells and nuclear apoptosis was determined at 24 h. Values in H and I are
means of triplicates   SEM. *P < 0.01 inhibition of chromatin condensation.1101 Castedo et al.
p53S15 (p53S15P) was confined to the nuclei of syncytia
(Fig. 1 C), and was not detected in SCs (Fig. 1 D).
p53S15P could be detected early (6 h) after syncytium for-
mation, well before Bax was overexpressed (Fig. 1 A and
B) and apoptotic chromatin condensation became detect-
able (Fig. 1 D). Among p53S15P  syncytia, only a fraction
exhibited a conformational change in Bax linked to mito-
chondrial translocation (Fig. 1 E) as well as the release of
Cyt. c from mitochondria (Fig. 1 F). Conversely, the trans-
location of Bax to mitochondria and of Cyt. c from
mitochondria was only found among p53S15P  (not
p53S15P ) syncytia (Fig. 1 G), indicating that these
changes occur after p53S15 phosphorylation. Accordingly,
inhibition of Cyt. c-mediated caspase activation by
Z-VAD.fmk (Fig. 1 H) or suppression of Bax translocation
by microinjection of recombinant Bcl-2 protein (36) into
syncytia (Fig. 1 I) failed to affect p53S15 phosphorylation.
Both Z-VAD.fmk and Bcl-2 did, however, prevent nu-
clear apoptosis as an internal control of their efficacy (Fig.
1 H and I). Altogether, these data place p53S15 phosphor-
ylation upstream of Bax upregulation/translocation, MMP,
and subsequent caspase activation.
p53S15 Phosphorylation Stimulates the Expression of
p53-transactivated Genes in HIV-1 Env-induced Syncytia.
p53S15 phosphorylation is known to increase the transacti-
vating function of p53 (37) and thus may contribute to
transcriptional activation of the bax gene (38) and apoptosis
induction (21). p53 is not mutated in HeLa cells (39), yet
has been reported to be functionally inactive due to the
presence of E6 from papilloma virus (40). However, evi-
dence that the low amount of p53 contained in HeLa cells
is functional has been reported (41, 42). It appears that
p53S15 phosphorylation of HeLa syncytia elicited by the
Env–CD4 interaction does result in transcriptional activa-
tion of p53 target genes, based on three lines of evidence.
First, expression of the Bax protein increases (Fig. 1 B), as
does that of Bax mRNA (data not shown). Second, the ex-
pression levels of two other prominent p53-activated gene
products, namely MDM2 (Fig. 2 A and C) and p21 (Fig. 2
B and C), increase upon syncytium formation, with a simi-
lar delay, and this enhanced expression is restricted to the
p53S15P  subpopulation of syncytia (Fig. 2 A and B).
Third, we employed a p53-inducible GFP construct that,
when transiently transfected into HeLa Env cells, cultured
in the absence of HeLa CD4 cells, fails to be expressed, un-
less it is cotransfected with p53 (but not with a dominant
negative p53 mutant, p53H175) (Fig. 2 D). Upon cocul-
ture with HeLa CD4 cells, this p53-inducible GFP con-
struct was strongly expressed in a subpopulation of
p53S15P  syncytia (but not in p53S15P  syncytia nor in
individual cells) (Fig. 2 E).
Figure 2. Activation of p53 transcriptional activity in syncytia. (A) In-
duction of MDM2 protein expression. Syncytia (18 h) were stained for
p53S15P and MDM2. Representative cells are shown. Note that strongly
MDM2-positive (green) nuclear structures were only detected in
p53S15P  (red) syncytia, whereas only a fraction of p53S15P  hetero-
karya were MDM2  (B). Induction of p21 protein expression as detected
by immunofluorescence. Again p21  cells were a subpopulation of
p53S15P  syncytia. (C) Kinetics of positive immunostaining in syncytia
for p53S15P, MDM2, p21, and Bax. Syncytia were subjected to immu-
nofluorescence staining as in B and C. Results are mean values   SD of
three independent cultures. (D) Expression of a p53-inducible reporter
gene in HeLa cells. HeLa Env cells were transfected with the p53-induc-
ible GFP construct alone (control, Co.) or together with p53 or a p53
dominant negative mutant (p53H175) and cultured alone for 48 h. Rep-
resentative cells stained with Hoechst 33342 are shown. The percentage
of control or p53H175-transfected cells exhibiting positive GFP fluores-
cence was  1%, that of p53-transfected cells 38   5% (n   3). (E) Induc-
tion of p53-inducible GFP in syncytia. HeLa Env cells were transfected
with a p53-inducible GFP construct (transfection efficiency  40%) and
fused 24 h later with HeLa CD4 cells. A subpopulation of 24-h-old
p53S15P  syncytia (70%) exhibited a diffuse GFP fluorescence.1102 HIV–Env–induced Apoptosis
p53S15 Phosphorylation in HIV-1 Infection In Vitro and In
Vivo. To validate our initial observations, obtained in
HeLa syncytia, we investigated whether p53S15P is in-
duced by HIV infection in vitro and in vivo. p53S15P was
induced in heterokaryons generated by coculturing HeLa
CD4 cells with a lymphoid cell line chronically infected
with a syncytium-inducing HIV-1 isolate (Fig. 3 A), as well
as in HIV-1–infected U937 myelomonocytary cells (Fig. 3
B), thus confirming that HIV-1 infection in vitro suffices
to induce p53S15P (22). Importantly, p53S15P was also
found among syncytia localized in the T cell area of lymph
nodes from HIV-1  patients (Fig. 3 C). Such cells also
expressed the preapoptotic marker tTgase (Fig. 3 C).
p53S15P was detected in PBMCs of HIV-1  donors but
not in PBMCs from HIV-1  controls ( 0.1% positive
cells) (Fig. 3 D). The frequency of p53Ser15P  PBMCs
correlated with the percentage of tTgase  cells (Fig. 3 E),
as well as with viral load (Fig. 3 F). In conclusion, p53S15P
is associated with HIV-1 infection, both upon in vitro in-
fection of human cells as and vivo, in patient-derived sam-
ples. p53S15P expression correlates with HIV-1 viremia
and preapoptosis.
p53S15 Phosphorylation Is Mediated by mTOR/FRAP.
p53S15 is known to be phosphorylated by stress kinases, in
particular ERK and p38 kinase (43), as well as by several
members of the PIKK family, in particular DNA-PK (44),
ATM (45), ATR (46), and mTOR/FRAP (47). Among a
large panel of serine kinases, phosphatases, and serine kinase
activators, the only two proteins whose expression level
changed in Env-induced syncytia were mTOR/FRAP,
which is upregulated, and the protein phosphatase PP2A,
which is downregulated (Fig. 4 A). PP2A is known to be
inhibited by mTOR/FRAP (48), suggesting that its late
(36 h) downregulation may be secondary to the upregula-
tion/activation of mTOR/FRAP detectable at 18 h.
Rapamycin (a specific inhibitor of mTOR/FRAP) and
LY294002 (a general inhibitor of PI-3 kinases including
mTOR/FRAP) significantly inhibited p53S15 phosphory-
Figure 3. p53S15P in HIV-1
infection. (A) p53S15P in HIV-1
infected syncytia. CD4-express-
ing HeLa cells were cocultured
with chronically HIV-1-infected
H9/IIIB cells at a 3:1 ratio and
stained for p53Ser15 (red), as
well as the mitochondrial matrix
protein hsp60 (green). The dom-
inant phenotypes obtained 12
and 48 h after coculture are
shown. (B) p53S15P in unin-
fected (Co.) or HIV-1–infected
U937 cells, as determined by im-
munoperoxidase staining (brown)
and hematoxylin counterstaining
(blue) and confirmed by immu-
noblot (inserts). (C) p53S15P 
syncytium in the apical light
zone of lymph node derived
from an HIV-1  donor (arrow).
On a consecutive section tTgase
expression was detected. The in-
sert show a p53S15P  syncytium
with condensed nuclei. Similar
pictures were obtained for five
different HIV-1 donors, whereas
no p53S15P  cells are detected
in HIV-1  controls (bottom). (D)
53S15P in PBMC derived from
representative HIV-1  (Co.) or
HIV-1  donors. Immunoper-
oxidase staining and immuno-
blots (inserts) are shown. (E)
Correlation between p53S15P
and tTgase expression in PBMC
from 49 HIV-1  patients. The
frequency of p53S15P  and
tTgase  cells was determined by
immunocytochemical analysis of
PBMC from 49 HIV-infected
individuals, at least 2 mo after in-
terruption of antiretroviral therapy (as in D). Each dot represents one HIV-infected patient. Statistics were calculated by means of the Pearson method for
parametric data using the GraphPad Prism statistical program. The correlation coefficient (Pearson r) is 0.7107. (F) Correlation between p53S15P and vi-
ral load of the same patients as in E. The correlation coefficient is 0.3922.1103 Castedo et al.
lation (Fig. 4 B). In contrast, the ERK inhibitor PD98059,
the p38 inhibitor SB203580, the ATM/DNA-PK inhibitor
wortmannin (49, 50) and the ATM/ATR inhibitor caf-
feine (46, 51) failed to prevent the syncytium-specific
p53S15 phosphorylation (Fig. 4 B). Accordingly, no phos-
phorylation of ERK (motif: pTEpY) or p38 kinase (motif:
pTGpY) was detectable in syncytia (data not shown), indi-
cating that these kinases are not activated. Moreover,
comet assays did not detect double- strand breaks among
nonapoptotic p53S15P  syncytia (Fig. 4 C and D), further
arguing against the implication of DNA-PK, ATM, and
ATR (all of which are, in principle, activated by double-
strand breaks; references 44–46) in p53S15 phosphoryla-
tion. As an alternative to rapamycin, microinjection of a
mAb specific for mTOR/FRAP into newly formed syncy-
tia caused a significant inhibition of p53S15 phosphoryla-
tion (Fig. 4 E). In conclusion, p53S15 phosphorylation is
mediated via mTOR/FRAP.
Cellular Alterations Induced by Activated mTOR/FRAP.
mTOR/FRAP mediates translational control via phosphor-
ylation of the p70s6k protein kinase and the 4E-binding
protein (4EBP) 1 (23, 24, 52). In a control experiment per-
formed on SCs, serum withdrawal (which inactivates
mTOR/FRAP) was found to cause the dephosphorylation
of p70s6k and 4EBP1 (lane 4 in Fig. 5 A), which were phos-
phorylated again upon readdition of serum (lane 5). This
serum-stimulated phosphorylation was fully inhibited by
rapamycin (lane 6) as an internal control of its efficacy. In
contrast, both SCs (lane 1) and syncytia (lane 2) cultured in
complete, serum-containing medium exhibited constitu-
tive phosphorylation of p70s6k and 4EBP (Fig. 5 A), as well
as constitutively high expression of a mTOR/FRAP-con-
trolled 5 -TOP-luciferase reporter construct (Fig. 5 B). Ac-
cordingly, the expression of several mTOR/FRAP-con-
trolled gene products including c-Myc, HIF-1, Rb, Rb2,
and signal transducer and activator of transcription 3 was
Figure 4. Mechanism of p53S15 phosphorylation. (A)
Alterations in the expression level of serine kinases and
phosphatases as determined by quantitative immunoblot
analysis. The percentage changes of the expression levels in
mTOR/FRAP and PP2a are shown (X   SEM, n   3).
*P   0.01. The right panel lists serine kinases and phos-
phatases, as well as related proteins, which were detectable
in HeLa cells and whose expression level varied  20%
within 18 or 36 h after syncytium formation. (B) Inhibi-
tory profile of p53S15 phosphorylation. HeLa Env and
HeLa CD4 cells were cocultured for 24 h in the presence
of the indicated agents, followed by determination of the
frequency of p53S15P  syncytia. Results are means of
three to five independent determinations   SEM. *P  
0.01, Student’s t test inhibitory effects. (C) Representative
comet assay results obtained for untreated HeLa CD4  SC
(negative control), H2O2-treated HeLa CD4  cells (posi-
tive control), adherent Env/CD4-induced syncytia (18 h),
or nonadherent, apoptotic Env/CD4-induced syncytia.
(D) Quantitation of comets (which reveal double-strand
breaks), as determined by image analysis (X   SD, n  
100). (E) Effect of microinjected mAb specific for
mTOR/FRAP on p53S15P. 6 h after fusion, syncytia
were microinjected with mAbs specific for mTOR/FRAP
or LAMP-1 (negative control), cultured for further 24 h,
and subjected to p53S15P staining. The asterisk indicates a
significant (P   0.01) inhibitory effect. Results are mean
values   SEM of three experiments.1104 HIV–Env–induced Apoptosis
not increased upon syncytium formation (data not shown).
Neither the constitutive phosphorylation of p70s6k  and
4EBP nor the translation of TOP-luciferase were inhibited
by a 24-h exposure to rapamycin (lane 3 in Fig. 5 A and B),
and rapamycin did not block the cell cycle of HeLa cells
(data not shown). In contrast, within the same time frame,
the fusion-dependent p53Ser15 phosphorylation was in-
hibited by rapamycin (Fig. 5 A). mTOR/FRAP coimmu-
noprecipitated with p53 and p53S15P in syncytia, not in
SCs (Fig. 5 C). Moreover, we found that in syncytia
mTOR/FRAP was enriched in the nucleus, as compared
with SCs. This alteration was observed both in p53S15P 
and p53S15P  syncytia (Fig. 5 D), and kinetic analyses re-
vealed that the nuclear accumulation of mTOR/FRAP
precedes the phosphorylation of p53S15P (Fig. 5 E). Alto-
gether, these data suggest that mTOR/FRAP is activated
in syncytia, where it directly phosphorylates p53 within the
nucleus. In contrast, other cytoplasmic targets of mTOR/
FRAP such as p70s6k and 4EBP1 are unlikely to explain the
rapamycin effects on syncytia.
Figure 5. Biological effects of FRAP on
syncytia. (A) Phosphorylation of the p70s6k
protein kinase, 4EBP1, and p53S15 in syn-
cytia. A 1:1 mixture of HeLa Env and HeLa
CD4 SCs (lane 1), 24-h-old syncytia cul-
tured in the absence (lane 2) or presence
(lane 3) of 1  M rapamycin, 30 h-serum-
deprived Env cells before (lane 4), or after
addition of serum for 3 h (lanes 5 and 6), in
the presence (lane 5) or absence of 1  M ra-
pamycin (lane 6) were subjected to SDS-
PAGE followed by immunodetection of
phosphorylated p70s6k (using a phosphospe-
cific mAb), 4EBP1 (note the reduced elec-
trophoretic mobility of the phosphorylated
protein), or p53S15P. (B) TOP-dependent
translation in syncytia. HeLa Env cells were
transiently transfected with a luciferase con-
struct containing TOP in the promoter re-
gion or a control construct lacking TOP.
These cells were mixed with an equivalent
amount of HeLa CD4 cells without cocul-
ture (1), or cocultured with HeLa CD4 cells
for 24 h, in the absence (2) or presence (3)
of 1  M rapamycin. Alternatively, the cells
were serum-deprived for 30 h and then cul-
tured for an additional 3 h in the absence (4)
or in the presence (5 and 6) of serum, with
(6) or without (5) 1  M rapamycin. Cellu-
lar extracts (50  g per point) were then pre-
pared and luciferase activities was deter-
mined. TOP-dependent luciferase activity
was divided by the TOP-independent lu-
ciferase activity and normalized assuming
that SCs cultured in the presence of serum
and in the absence of rapamycin (1 and 5)
represent 100% TOP-dependent transla-
tion. (C) Coimmunoprecipitation of
mTOR/FRAP and p53S15P  in syncytia.
Ad hoc mixtures of HeLa Env and HeLa
CD4 SCs, 24-h-old syncytia (Syn) were
lysed and then subjected to immunoprecipi-
tation with antisera specific for p53, p53S15P,
or Bcl-2 (negative control), SDS-PAGE,
and immunodetection of mTOR/FRAP.
(D) Enhanced expression of mTOR/FRAP
in syncytia. As compared with SCs (arrows),
syncytia manifest an enhanced, mainly nu-
clear staining for mTOR/FRAP. Two 12-
h-old syncytia representing the two major
phenotypes are shown: mTOR/
FRAPhighp53Ser15P  and mTOR/
FRAPhighp53Ser15P . Note that all
p53Ser15P  syncytia were mTOR/FRAPhigh, whereas mTOR/FRAPhigh syncytia were either p53Ser15P  or p53Ser15P . (E) Quantitation of the fre-
quency of mTOR/FRAPhigh and p53Ser15P  cells at different time points.1105 Castedo et al.
Inhibition of mTOR/FRAP or p53S15 Phosphorylation
Prevents Env-induced Syncytial Apoptosis. When added to
HeLa Env/HeLa CD4 cocultures, rapamycin and
LY294002 inhibited all signs of syncytial apoptosis, includ-
ing the loss of the   m (indicated by a red→green shift of
the fluorescence emitted by the   m-sensitive fluoro-
chrome JC-1), chromatin condensation (detected with the
blue fluorochrome Hoechst 33342) (Fig. 6 A and B), the
translocation of Bax to mitochondria, and the Bax-medi-
ated release of Cyt. c from mitochondria (Fig. 6 B). Con-
comitantly, rapamycin and LY294002 allowed for the
formation of larger syncytia (Fig. 6 C), an effect quantita-
tively similar to what could be seen with the pancaspase
inhibitor Z-VAD.fmk (Fig. 6 C and reference 6). The
apoptosis-inhibitory effect of rapamycin was durable, with
a strong inhibitory effect on apoptosis of 6-d-old syncytia
(81   4% of viable,   m
high syncytia with 1  M rapamy-
cin versus only 25   3%   m
high syncytia in untreated
controls, n   3). The antiapoptotic effects of rapamycin
and LY294002 were observed at doses similar to those
required for inhibition of p53S15 phosphorylation (Fig.
4 B). In contrast, wortmannin, caffeine, PD98059,
SB203580, CsA, or FK506, which do not affect p53S15
phosphorylation (Fig. 4 B), also failed to prevent apoptosis
(Fig. 6 D). Thus, a large panel of agents which inhibit
apoptosis in other experimental systems failed to prevent
syncytial apoptosis, with the notable exception of pyrroli-
dine dithiocarbamate (PDTC, Fig. 6 G), a pleiotropic
agent known to interfere with p53 function (53, 54). Of
note, PDTC also reduced the phosphorylation of p53S15
Figure 6. Apoptosis inhibition by rapamycin and
LY294002 in Env/CD4-induced syncytia. (A) Repre-
sentative JC-1/Hoechst 33342 staining of syncytia gen-
erated by 48 h of coculture in the absence (control) or
presence of 1  M rapamycin. Cells were stained with
Hoechst 33342 (blue fluorescence) and the   m-sensi-
tive dye JC-1 (red fluorescence of mitochondria with a
high   m, green fluorescence of mitochondria with a
low   m). Note that rapamycin antagonizes the   m
loss, as well as chromatin condensation. (B) Inhibition
of mitochondrial and nuclear signs of apoptosis. Cocul-
tures (48 h) of HeLa Env and HeLa CD4 cells were
performed in the presence of rapamycin or LY294002,
followed by quantitation of the   m loss and chroma-
tin condensation on live cells (determined as in A) or,
alternatively, permeabilization, fixation and immu-
nostaining with an anti-Bax or anti-Cyt. c antibody (as
in Fig. 1 E and F). Asterisks indicate significant (P  
0.01) inhibitory effects. (C) Quantitation of the num-
ber of nuclei per syncytium (n   100) after 72 h of
coculture. The pancaspase inhibitor Z-VAD.fmk (100
 M, added at the beginning of coculture) was included
as a positive control. *P   0.01). (D) Effects of apopto-
sis-regulatory compounds on syncytia. The effect of
different agents on nuclear apoptosis were assessed as in
A. “No effect” denotes  20% inhibition or enhance-
ment of chromatin condensation. “Toxicity” and
“protection” denote  20% increase or reduction of
apoptosis, respectively. PDTC inhibited apoptosis by
52   6% in three independent experiments.1106 HIV–Env–induced Apoptosis
(Fig. 4 B), underlining the intimate relationship between
p53S15P and syncytial apoptosis.
p53 Participates in Syncytial Apoptosis. To directly assess
the role of p53 in syncytial apoptosis, Env and CD4/
CXCR4-expressing cells were transiently transfected with
two dominant negative (DN) p53 constructs (p53H175
and p53H273) 24 h before fusion. As compared with vec-
tor-only control transfections, DN-p53 conferred protec-
tion against all the mitochondrial and nuclear hallmarks of
syncytial apoptosis including the translocation of Bax to
mitochondria (Fig. 7). This protection was partial ( 50%),
in agreement with the transfection efficiency ( 50%).
These data indicate that the mTOR/FRAP→p53S15P
pathway delineated here dictates the fate of Env-induced
syncytia at the premitochondrial level, upstream of the up-
regulation of Bax. To address the involvement of p53 in
syncytial apoptosis in a completely different experimental
setting, MEFs with different p53 genotypes were subjected
to short-term exposure to PEG, resulting in their fusion. In
wild-type MEFs (p53 / ), syncytium formation led to
phosphorylation of p53S15, positive staining for Bax (Fig. 8
A), and apoptotic cell death (Fig. 8 B), whereas syncytia
formed from p53 /  MEFs (which obviously do not stain
for p53S15P) failed to activate Bax (Fig. 8 A) and to un-
dergo apoptosis (Fig. 8 B). In conclusion, p53 is rate-limit-
ing for apoptosis triggered by syncytium formation.
mTOR/FRAP Inhibition Prevents Syncytial Apoptosis In-
duced by HIV-1 Infection. HeLa CD4 cells cocultured with
H9 lymphoid cells chronically infected with the HIV-1
strain IIIb can form syncytia, which undergo apoptosis.
Syncytial apoptosis was inhibited by rapamycin, both at the
mitochondrial and the nuclear levels (Fig. 9 A and B). To
further substantiate the rapamycin-mediated inhibition of
syncytial cell death, CEM T lymphoma cells engineered to
contain a GFP gene under the control of the HIV-1 LTR
promoter (normally inactive) were cocultured with HIV-1
IIIb-infected H9 cells, in the presence of absence of rapa-
mycin. Upon formation of syncytia, HIV-1–encoded Tat
transactivates LTR and induces GFP expression (33). In the
presence of rapamycin (or Z-VAD.fmk, as a positive con-
Figure 7. Apoptosis inhibition by dominant negative p53. Both HeLa
Env and HeLa CD4 cells were transfected by p53H175 or p53 H273, as
well as a vector control only (Co.). 24 h after the transfection the cells
were cocultured for 48 h and the mitochondrial and nuclear parameters
indicative of apoptosis were assessed by JC1/Hoechst 33342 or immuno-
fluorescence staining, as detailed in Materials and Methods. Asterisks indi-
cate significant (P   0.01) inhibitory effects, as compared with vector-
only-transfected cells. The insert demonstrates the transfection-enforced
overexpression of mutant p53, as determined by immunoblotting. Results
are representative of four independent determinations.
Figure 8. p53 is required for syncytial apoptosis. Wild-
type (p53 / ), p53 / , and p53 /  cells were fused by
transient exposure to PEG. (A) Syncytia (9 h) arising from
p53 /   MEF showing positive immunoreactivity after
staining for p53S15P or Bax. Note that Bax  cells were also
positive for p53S15P. As a control, a representative p53 / 
syncytium (which stays Bax ) is shown. (B) Quantitation of
apoptosis. Syncytia arising from the fusion of p53 / ,
p53 / , or p53 /  cells were stained at the indicated time
points with JC1/Hoechst 33342 (as in Fig. 6 A) and the
frequency of cells exhibiting a low   m and chromatin
condensation was determined. Results are representative of
three independent experiments.1107 Castedo et al.
trol) the frequency of viable syncytia was increased, leading
to an enhanced GFP-dependent fluorescence (Fig. 9 C).
When individual nuclei from such syncytia were subjected
to cytofluorometric DNA content analysis, the frequency
of hypoploid (apoptotic) nuclei was found to be strongly
reduced by rapamycin (Fig. 9 D). In a further series of ex-
periments, primary CD4  lymphoblasts from healthy do-
nors were infected by HIV-1 IIIb in vitro, a manipulation
that induced syncytium formation and subsequent apopto-
sis. Addition of rapamycin 48 h after infection did not af-
fect viral replication, as determined by measuring the pro-
duction of p24 (Fig. 9 E). However, rapamycin did inhibit
chromatin condensation and led to an increase in the num-
ber of nuclei per syncytium, similar to Z-VAD.fmk (Fig. 9
E). Thus, the cytoprotective effects of rapamycin on lym-
phoblasts infected with HIV-1 cannot be attributed to an
inhibition of viral replication or syncytium formation. Ra-
pamycin inhibited the phosphorylation of p53S15 in HIV-
infected cells (Fig. 9 B). Taken together, these data confirm
that the rapamycin-inhibited mTOR/FRAP→p53S15P
pathway selectively controls apoptosis of syncytia in human
primary CD4  lymphocytes infected by HIV-1.
Concluding Remarks. As shown here, HIV-1-Env–induced
syncytium formation leads to apoptosis via a pathway
that involves p53S15 phosphorylation by mTOR/FRAP.
This corroborates the role of p53 as a major point of inte-
Figure 9. Rapamycin effects on syncytial apoptosis in-
duced by HIV-1 infection. (A) Fluorescence micrographs of
HeLa CD4 cells cocultured with HIV-1–infected H9/IIIB
cells for 48 h in the absence (Co.) or the presence of 1  M
rapamycin. Cells were stained with Hoechst 33342 and the
  m-sensitive dye JC-1 (as in Fig. 6 A). Primary CD4 
lymphoblasts infected with HIV-1 IIIb are also shown. (B)
Rapamycin effects on p53S15P and apoptosis in HeLa
CD4 cells cocultured with H9/IIIB cells. p53S15P was de-
termined by immunofluorescence as in Fig. 1 C and apop-
tosis was measured by staining with JC-1/Hoechst. Values
refer to the percentage of syncytia that are p53S15P  or
apoptotic. Asterisks denote significant (P   0.01) effects of
rapamycin, as compared with untreated cocultures. (C and
D) Rapamycin-enhanced viability of syncytia associated
with apoptosis inhibition. CEM cells stably transfected
with a Tat-inducible GFP or HIV-1–infected H9/IIIB
cells were cultured alone or cocultured (CC), in the ab-
sence or presence of AMD3100 (1  g/ml), Z-VAD.fmk
(50  M), or rapamycin (1  M). GFP-dependent fluores-
cence (arbitrary units, a.u.) was measured to assess the total
syncytial mass (C). Parallel cultures were subjected to lysis,
staining with propidium iodine, and cytofluorometric de-
termination of the percentage (X   SEM, n   3) of hy-
poploid (sub-G1) nuclei (D). (E) Rapamycin effects on
apoptosis of HIV-1 infected primary CD4  lymphoblasts.
2 d after infection with HIV-IIIB, the inhibitors
AMD3100 (which prevents the Env/CD4 interaction, 5
 g/ml), 100  M Z-VAD.fmk, or rapamycin were added
to the cultures. At day 4, the production of p24 ( 0.5 ng/
ml on day 2) was determined. In addition the frequency of
syncytia with condensed nuclei and the number of nuclei
per syncytium were determined. Results are mean val-
ues   SEM of three independent experiments. Asterisks
denote significant (P   0.01) effects as compared with
control cultures.1108 HIV–Env–induced Apoptosis
gration of proapoptotic signaling and damage sensing (21).
The data presented here unravel that p53 is rate limiting for
the apoptotic demise of syncytia. It is tempting to speculate
that p53 could be generally required for the clearance of
nonphysiological polyploid cells (syncytia or plasmodia).
Indeed, HeLa cells transfected with antisense p53 spontane-
ously form giant multinucleate cells (41); antisense oligonu-
cleotides suppressing p53 expression induce polyploidy in
regenerating rat liver (55); and p53 /  mice accumulate
multinucleate cells in the testis (56) as well as in the prostate
epithelium (57). However, further studies are required to
distinguish the relative impact of p53 on the prevention of
nuclear endoreplication and the illicit survival of polyploid
cells in these model systems.
The role of mTOR/FRAP in apoptosis control is far less
established than p53. The mTOR/FRAP analogues of S.
cerevisae and Drosophila are known to play a major role in
the control of cell size (24, 25). External constraints on cell
size and shape have a profound effect on HIV-1-Env–
induced syncytial apoptosis (58). It thus may be possible
that the abnormal size or the distorted volume/surface ratio
of syncytia, sensed via yet unknown mechanisms, activate the
mTOR/FRAP pathway and consequent cellular demise.
Alternatively or in addition, signals triggered via the Env-
CD4/CXCR4 interaction might stimulate the mTOR/
FRAP pathway. In some cell types, the mTOR/FRAP an-
tagonist rapamycin induces apoptosis (59) via a p53-indepen-
dent pathway (60), indicating that mTOR/FRAP can also
act as an endogenous cell death antagonist. Indeed,
mTOR/FRAP mediates survival signals received through
the receptors for IL-3, insulin, and insulin-like growth fac-
tor (61, 62) and may participate in oncogenic transforma-
tion (26). mTOR/FRAP is constitutively active in mam-
malian cells, at least in the presence of serum and nutrients
(24, 52), suggesting that the cellular context rather than the
expression level of mTOR/FRAP dictates whether its
proapoptotic or antiapoptotic function prevails.
In the context of HIV-1-Env–induced syncytia,
mTOR/FRAP-mediated p53S15 phosphorylation appears
to contribute to apoptosis by activating Bax (and perhaps
other proapoptotic proteins) and consecutive MMP. In-
triguingly, a fraction of lymph node cells from HIV-1  do-
nors are p53S15P  (this paper), express (p53-inducible, ref-
erence 63) tTgase (15), and exhibit a   m loss (64, 65),
suggesting that they die via a pathway similar to that delin-
eated for Env-induced syncytial apoptosis. Pharmacological
targeting of the mitochondrial or premitochondrial events
involved in HIV-1–associated apoptosis may thus offer a
novel opportunity to intervene on AIDS pathogenesis.
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